ArticleGastrointestinal tumors2017
Freezing Fort Knox: Mesenteric Carcinoid Cryoablation.
Article in Gastrointestinal tumors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 7 citations in OpenAlex.
- Modern cancer therapy: cryoablation meets immune checkpoint blockade.Frontiers in oncology · 2024Review
- Radiotherapy, photodynamic therapy, and cryoablation-induced abscopal effect: Challenges and future prospects.Cancer innovation · 2023Review
- Inferior Vena Cava Syndrome as a Manifestation of Metastatic Carcinoid Tumor.Gastrointestinal tumors · 2021Article
- Article
- Rare Treatment for a Rare Tumor: Cryoablation of a Granular Cell Tumor.Gastrointestinal tumors · 2020Article
- Management of Gastrointestinal Neuroendocrine Tumors.Clinical medicine insights. Endocrinology and diabetes · 2019Review
- Finally, a Minimally Invasive Option for Intrahepatic Inferior Vena Cava Invasion by Hepatocellular Carcinoma.Gastrointestinal tumors · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroendocrine malignancy is indolent, yet relentless in its propensity to metastasize to the liver, where it may cause bizarre paraneoplastic syndromes. The pathophysiologic mechanism behind this predilection for hepatic metastasis is twofold: the portal venous system drains the most likely primary sites for neuroendocrine tumors, and the relatively immunosuppressed environment within the hepatic parenchyma is permissive for tumor growth. The standard of care for patients with metastatic neuroendocrine tumor is surgical resection of at least 90% of the tumor burden.
methodsThis report describes CT-guided percutaneous cryoablation of an inoperable mesenteric carcinoid tumor that had previously demonstrated hepatic metastases utilizing hydrodissection to safely and effectively prevent further metastasis while priming the immune system to eradicate this malignancy systemically.
resultsCT-guided percutaneous cryoablation is minimally invasive, has intrinsic analgesic properties, and may contribute to sensitization of the immune system against tumor antigens.
conclusionPercutaneous cryoablation with hydrodissection can be used to target intraabdominal malignancy in poor surgical candidates. This procedure is safe, effective, and minimally invasive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.